Previous Close | 10.31 |
Open | 10.36 |
Bid | 9.90 x 100 |
Ask | 10.55 x 100 |
Day's Range | 10.01 - 10.64 |
52 Week Range | 5.42 - 24.57 |
Volume | 199,093 |
Avg. Volume | 319,691 |
Market Cap | 143.208M |
Beta | 4.94 |
PE Ratio (TTM) | N/A |
EPS (TTM) | -2.48 |
Earnings Date | Aug 9, 2017 - Aug 14, 2017 |
Forward Dividend & Yield | N/A (N/A) |
Ex-Dividend Date | N/A |
1y Target Est | 17.81 |
GW Pharmaceuticals, Insys Therapeutics and Zynerba Pharmaceuticals are using cannabis-based therapies to treat a myriad of disorders, including seizures.
DEVON, Pa., April 16, 2018-- Zynerba Pharmaceuticals, Inc., a clinical-stage specialty neuropsychiatric pharmaceutical company dedicated to developing and commercializing innovative pharmaceutically-produced ...
DEVON, Pa., April 10, 2018-- Zynerba Pharmaceuticals, Inc., a clinical-stage specialty neuropsychiatric pharmaceutical company dedicated to developing and commercializing innovative pharmaceutically-produced ...
Zynerba Pharmaceuticals Inc (NASDAQ:ZYNE), a pharmaceuticals company based in United States, received a lot of attention from a substantial price movement on the NasdaqGM in the over the last fewRead More...
DEVON, Pa., March 26, 2018-- Zynerba Pharmaceuticals, Inc., a clinical-stage specialty neuropsychiatric pharmaceutical company dedicated to developing and commercializing innovative pharmaceutically-produced ...
DEVON, Pa., March 22, 2018-- Zynerba Pharmaceuticals, Inc., a clinical-stage specialty neuropsychiatric pharmaceutical company dedicated to developing and commercializing innovative pharmaceutically-produced ...
Zynerba Pharmaceuticals Inc’s (NASDAQ:ZYNE): Zynerba Pharmaceuticals, Inc. operates as a clinical stage specialty pharmaceutical company. The US$136.43M market-cap company announced a latest loss of -US$32.01M on 31 December 2017 forRead More...
DEVON, Pa., March 14, 2018-- Zynerba Pharmaceuticals, Inc., a clinical-stage specialty neuropsychiatric pharmaceutical company dedicated to developing and commercializing innovative pharmaceutically-produced ...
NEW YORK, NY / ACCESSWIRE / March 13, 2018 / U.S. markets were mixed Mondays as concerns over a potential trade war overshadowed Friday’s jobs data. The Dow Jones Industrial Average declined 0.62 percent ...
The Devon, Pennsylvania-based company said it had a loss of 60 cents per share. The results exceeded Wall Street expectations. The average estimate of five analysts surveyed by Zacks Investment Research ...
DEVON, Pa., March 12, 2018--. Zynerba Pharmaceuticals, Inc., a clinical-stage specialty neuropsychiatric pharmaceutical company dedicated to developing and commercializing innovative pharmaceutically-produced ...
Stock Monitor: Horizon Pharma Post Earnings Reporting LONDON, UK / ACCESSWIRE / March 07, 2018 / Active-Investors.com has just released a free research report on Zynerba Pharma, Inc. (NASDAQ: ZYNE ). If ...
Zynerba Pharmaceuticals said Monday it plans — with the Food and Drug Administration's approval — to initiate a single pivotal study later this year to support a new drug application for its experimental cannabis-based treatment for Fragile X Syndrome. Fragile X is a rare genetic developmental disability that is a leading known cause of both inherited intellectual disability and autism spectrum disorder. Zynerba, of Devon, Pa, said its game plan for its new drug candidate, ZYN002, came following a meeting with the Food and Drug Administration.
DEVON, Pa., March 05, 2018-- Zynerba Pharmaceuticals, Inc., a clinical-stage specialty neuropsychiatric pharmaceutical company dedicated to developing and commercializing innovative pharmaceutically-produced ...
While Zynerba's share price is still roughly half of last year's peak, the company has gotten attention from Wall Street with big upside in analyst calls in recent days.
Zynerba faces some big questions heading into the new year.
For investors, increase in profitability and industry-beating performance can be essential considerations in an investment. Below, I will examine Zynerba Pharmaceuticals Inc’s (NASDAQ:ZYNE) track record on a high level, toRead More...
NEW YORK, NY / ACCESSWIRE / December 5, 2017 / U.S. markets saw mixed Monday as the Dow reached a new record after investors celebrated the passing of a bill to overhaul the country's tax system while ...
Shares of Zynerba Pharmaceuticals Inc (NASDAQ: ZYNE ), a specialty pharmaceutical company that focuses on developing and commercializing pharmaceutically produced transdermal cannabinoid treatments, traded ...
Zynerba Pharmaceuticals Inc (NASDAQ:ZYNE), a pharmaceuticals company based in United States, received a lot of attention from a substantial price increase on the NasdaqGM in the over the last fewRead More...
On a per-share basis, the Devon, Pennsylvania-based company said it had a loss of 63 cents. The results fell short of Wall Street expectations. The average estimate of four analysts surveyed by Zacks Investment ...